Companies
Analyst’s Sets ResMed Inc. (NYSE:RMD) New Target at $211.40: RMD is Now On A Buy List
ResMed Inc. (NYSE:RMD) has a beta of 0.29, a 12-month trailing P/E ratio of 75.69, and a growth ratio of 3.71. The stock’s Relative Strength
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.